Press release
Head and Neck Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Debiopharm, Merck, GlaxoSmithKline, QBiotics Group Limited, Memgen, Inc
Head and Neck Cancer Pipeline Analysis
Head and Neck Cancer Pipeline constitutes 80+ key companies continuously working towards developing 100+ Head and Neck Cancer treatment therapies, analyzes DelveInsight.
Head and Neck Cancer Overview:
Head and neck cancer (HNC) includes a group of malignancies that typically arise in the squamous cells lining the mucosal surfaces of the mouth, throat, and larynx. These are known as squamous cell carcinomas. Less commonly, HNC can also originate in the salivary glands, sinuses, muscles, or nerves. Common affected areas include the oral cavity, pharynx, larynx, nasal cavity, and salivary glands.
The development of HNC is driven by genetic and epigenetic alterations, such as mutations in tumor suppressor genes (like TP53), activation of oncogenes (like EGFR), and disruptions in signaling pathways (e.g., PI3K/AKT and MAPK). Key risk factors include tobacco and alcohol use, and HPV infection, particularly in oropharyngeal cancers.
Diagnosis involves reviewing medical history, symptoms, and risk factors, followed by physical exams, imaging (like CT scans), and biopsies to confirm cancer and detect HPV. Further testing determines the cancer stage, which helps guide treatment decisions.
Treatment options vary based on cancer type, stage, and patient health, and may include surgery, radiation, chemotherapy, targeted therapy, or immunotherapy. Patients with HPV-positive oropharyngeal cancer tend to have better outcomes, prompting clinical trials to explore less aggressive treatments like reduced radiation or immunotherapy for these cases.
Request for a detailed insights report on Head and Neck Cancer pipeline insights [https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Head and Neck Cancer Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Head and Neck Cancer Therapeutics Market.
Key Takeaways from the Head and Neck Cancer Pipeline Report
*
DelveInsight's Head and Neck Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Head and Neck Cancer treatment.
*
In September 2022, NANOBIOTIX announced the randomization of the first patient in Asia for NANORAY-312, a global Phase III trial evaluating NBTXR3 in elderly patients with locally advanced head and neck squamous cell carcinoma (HNSCC) who are ineligible for platinum-based chemotherapy.
*
In August 2022, Genexine began dosing the first patient in a Phase II clinical trial investigating a triple combination therapy for recurrent/metastatic HNSCC. This therapy combines two of Genexine's proprietary drugs, GX-188E (a therapeutic DNA vaccine) and GX-I7 (a long-acting interleukin-7), with Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor.
*
In May 2022, Calliditas Therapeutics initiated a Phase II trial to evaluate the combination of setanaxib and pembrolizumab in patients with CAF-density tumors. The first subject was randomized in this proof-of-concept study targeting squamous cell carcinoma of the head and neck (SCCHN).
*
In May 2022, Exelixis shared results from a Phase II investigator-sponsored trial of cabozantinib (CABOMETYX Registered ) with pembrolizumab in recurrent or metastatic HNSCC. The trial achieved an objective response rate of 54% (per RECIST version 1.1), with an overall clinical benefit rate of 91%. Median progression-free survival was 14.6 months, and the one-year overall survival rate was 68.4%.
*
In January 2022, the FDA accepted an investigational new drug application for RM-1995, a photoimmunotherapy treatment designed for patients with advanced cutaneous squamous cell carcinoma or head and neck squamous cell carcinoma.
*
Key Head and Neck Cancer companies such as Debiopharm, Merck, GlaxoSmithKline, QBiotics Group Limited, Memgen, Inc., BioNTech, Alentis Therapeutics AG, Beijing CorreGene Biotechnology, Coordination Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Sichuan Baili Pharmaceutical Co., Ltd., TILT Biotherapeutics Ltd., Coherus Biosciences, Inc., and others are evaluating new drugs for Head and Neck Cancer to improve the treatment landscape.
*
Promising Head and Neck Cancer pipeline therapies in various stages of development include Xevinapant, Dostarlimab, Tigilanol tiglate, MEM-288, and others.
Head and Neck Cancer Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Head and Neck Cancer Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Head and Neck Cancer treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Head and Neck Cancer market.
Download our free sample page report on Head and Neck Cancer pipeline insights [https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Head and Neck Cancer Emerging Drugs
*
Xevinapant: Debiopharm/Merck
*
Dostarlimab: GlaxoSmithKline
*
Tigilanol tiglate: QBiotics Group Limited
*
MEM-288: Memgen, Inc.
Head and Neck Cancer Companies
More than 80 prominent companies are currently developing treatments for head and neck cancer. Among these, GlaxoSmithKline and Debiopharm/Merck have drug candidates that are in the most advanced phase of development-Phase III clinical trials.
DelveInsight's report covers around 100+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Head and Neck Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Head and Neck Cancer Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Head and Neck Cancer Therapies and Key Companies: Head and Neck Cancer Clinical Trials and advancements [https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Head and Neck Cancer Pipeline Therapeutic Assessment
- Head and Neck Cancer Assessment by Product Type
- Head and Neck Cancer By Stage
- Head and Neck Cancer Assessment by Route of Administration
- Head and Neck Cancer Assessment by Molecule Type
Download Head and Neck Cancer Sample report to know in detail about the Head and Neck Cancer treatment market @ Head and Neck Cancer Therapeutic Assessment [https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Head and Neck Cancer Current Treatment Patterns
4. Head and Neck Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Head and Neck Cancer Late-Stage Products (Phase-III)
7. Head and Neck Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Head and Neck Cancer Discontinued Products
13. Head and Neck Cancer Product Profiles
14. Head and Neck Cancer Key Companies
15. Head and Neck Cancer Key Products
16. Dormant and Discontinued Products
17. Head and Neck Cancer Unmet Needs
18. Head and Neck Cancer Future Perspectives
19. Head and Neck Cancer Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Head and Neck Cancer Pipeline Reports Offerings [https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=head-and-neck-cancer-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-and-pipeline-analysis-debiopharm-merck-glaxosmithkline-qbiotics-group-limited-memgen-inc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Head and Neck Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Debiopharm, Merck, GlaxoSmithKline, QBiotics Group Limited, Memgen, Inc here
News-ID: 4105417 • Views: …
More Releases from ABNewswire
Denver's Best Appliance Repair Responds to Rising Demand for Emergency Appliance …
Denver's Best Appliance Repair expands emergency services across the Denver metro with same-day repairs, 7-day availability, 5-year parts warranty, and professional licensed technicians serving residential and commercial clients.
Household appliance failures don't follow a schedule. When a refrigerator stops cooling in the middle of summer or a washing machine floods a basement on a Sunday evening, families need immediate help. Denver's Best Appliance Repair has responded to this growing need by…
Oak Hill Clinic Reaches 30,000 Client Milestone with Results-Driven Deep Tissue …
Deep Relief in Oak Hill, Austin, has served 30,000 clients through specialized massage, chiropractic, and acupuncture care. The clinic accepts insurance and focuses on results-driven treatments for pain relief.
Deep Relief, an Oak Hill-based wellness clinic, has achieved a significant milestone by serving more than 30,000 clients seeking Relief from chronic pain, muscle tension, and mobility issues. The clinic's success stems from its commitment to advanced, results-focused bodywork that goes beyond…
Vertex Fleet Expands Nationwide Network to Combat Growing Trailer Drop Yard Shor …
Vertex Fleet announces major expansion of secure parking facilities nationwide, addressing the critical shortage of commercial vehicle storage with 15+ new locations featuring 24/7 security and technology-driven access.
The freight and logistics industry faces a mounting crisis as demand for secure parking spaces continues to outpace supply across the United States. Vertex Fleet [https://www.vertexfleet.com/], a leading provider of industrial outdoor storage solutions, has announced significant expansion plans to address this critical…
HVAC in Denver Sees Service Enhancement as Denver's Best Heating and AC Repair L …
Denver's Best Heating and AC Repair expands 24/7 emergency services across 23 metro cities, offering A+ rated heating, cooling, and commercial HVAC solutions with rapid response times and multi-brand expertise.
Denver's Best Heating and AC Repair [https://www.denversbestheatingandacrepair.com/]has expanded its service capabilities to meet growing demand for reliable heating and cooling solutions across the Denver Metro area. The A+ rated contractor now provides 24/7 emergency response services to 23 cities, addressing critical…
More Releases for Head
Green Dot Sign® Going Head-to-Head with Traditional Plastic ADA Signs
After the success of their groundbreaking sustainable ADA compliant interior signs, Green Dot Sign® is now offering a more affordable and adaptable option than ever before: Low profile office signs.
Nussbaum started considering environmentally-friendly manufacturing methods and products while working at his prior sign company. The idea to create signage from a wood base and non-toxic 3D printed material for lettering, braille, and pictograms was sparked by a braille sign with…
China and India are growing head to head in Companion Diagnostic market
“Asia-Pacific Companion Diagnostics Market" research report, published by Market Data Forecast estimates that the market is growing with a CAGR of 27.91% to reach USD 2.17 billion by 2021, from USD 0.63 billion in 2016, which amounts to a cumulative growth of USD 1.54 billion.
A companion diagnostics device is a medical device that provides information which is necessary for drug safety and effectives or any other biological product. This helps…
East and West going head to head in Asia-Pacific Food Emulsifiers Market
Asia-Pacific Food Emulsifiers Market" research report, published by Market Data Forecast delineates that the market is growing with a CAGR of 6.15% to reach USD 0.78 billion by 2021, from USD 0.58 billion in 2016, which amounts to a cumulative growth of USD 0.20 billion.
View Full Report at http://www.marketdataforecast.com/market-reports/asia-pacific-food-emulsifiers-market-564/
Download Free Sample report at http://www.marketdataforecast.com/market-reports/asia-pacific-food-emulsifiers-market-564/request-sample
A substance used in food manufacturing which helps to combine liquids of different thicknesses is known as…
dinCloud Earns Top Marks in Head-to-Head Comparison
The #1 Brand in Hosted Virtual Desktops
LOS ANGELES, CA – June 19, 2012 – dinCloud, a cloud transformation company and provider of hosted virtual desktops, has come out on top as the leading provider of DaaS (Desktop as a Service) in a head-to-head comparison of five market leaders by ExtremeLabs. dinCloud’s solution received the groupings highest marks for the solution’s good control, as well as fast response, and was the…
University Students go head to head in University of Bolton’s “Sports Fiesta …
The University of Bolton Student’s Council and the Student Activities Department organized an integrated program of sporting activities around the theme "Sports Fiesta 2012" which drew a number of Universities from the Northern Emirates and Dubai.
The activities took place at UOB RAK Campus. Separate activities for male and female attendees included; badminton, basketball, chess, cricket, darts, tug-o-war, sprint race, football and volleyball matches, and other recreational games.
To coincide with the…
KnowledgetoAction Departments Go Head to Head in a Bowling Competition
London, UK ( ) October 25, 2010 - Employees of KnowledgetoAction (http://knowledgeandaction.co.uk) have been going head to head against each other in a series of team building competitions that began on September 1, 2010. Knowledge to Action believes strongly in team building and this event showcased their desire for excellent team cooperation and communication between departments, allowing for more cohesiveness within Knowledge to Action.
Most recently, each of the KnowledgetoAction…
